Study on Chinese Medicine Combined with Chemotherapy for Treatment of 32 Cases of Advanced Pancreatic Cancer

Shen Yehua; Liu Luming; Chen Zhen; et al.

doi:10.13288/j.11-2166/r.2006.02.026

您当前的位置：

首页 >

文章列表页 >

Study on Chinese Medicine Combined with Chemotherapy for Treatment of 32 Cases of Advanced Pancreatic Cancer

更新时间：2021-11-21

- Study on Chinese Medicine Combined with Chemotherapy for Treatment of 32 Cases of Advanced Pancreatic Cancer
- Journal of Traditional Chinese Medicine Issue 2, Pages: 115-117(2006)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院中医科
  2. 复旦大学附属肿瘤医院中医科上海市东安路270号,200032
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2006.02.026
  CLC： R735.9
- Published：2006
- 稿件说明：
移动端阅览
[1]沈晔华,刘鲁明,陈震,孟志强,宋明志,于尔辛.中药联合化疗治疗晚期胰腺癌32例临床研究[J].中医杂志,2006(02):115-117.

Shen Yehua, Liu Luming, Chen Zhen, et al. Study on Chinese Medicine Combined with Chemotherapy for Treatment of 32 Cases of Advanced Pancreatic Cancer[J]. Journal of Traditional Chinese Medicine2006, (2): 115-117.
[1]沈晔华,刘鲁明,陈震,孟志强,宋明志,于尔辛.中药联合化疗治疗晚期胰腺癌32例临床研究[J].中医杂志,2006(02):115-117. DOI： 10.13288/j.11-2166/r.2006.02.026.

Shen Yehua, Liu Luming, Chen Zhen, et al. Study on Chinese Medicine Combined with Chemotherapy for Treatment of 32 Cases of Advanced Pancreatic Cancer[J]. Journal of Traditional Chinese Medicine2006, (2): 115-117. DOI： 10.13288/j.11-2166/r.2006.02.026.

摘要

目的:通过期胰腺癌患者治疗后回顾性研究

比较中药治疗及动脉灌注化疗的临床疗效和价值。方法:2002年5月

004年7月期间依次入院的60例患者分为两组作为研究对象（其中中药组32例、化疗组28例）

两组基本情况差异无显著性（P

0.05）。观察比较两组治疗后客观有效率、生存期、无进展生存期以及药物不良反应。结果:中药组治疗后客观有效率为部分缓解（PR）0、稳定（SD）53.1%、进展（PD）46.9%

化疗组为PR7.1%、SD53.6%、PD39.3%

两组差异无显著性（P

0.05）。中药组一年生存率为34.37%

中位生存期6.07个月

明显优于化疗组（一年生存率11.25%、中位生存期4.17个月）

差异有显著性（P

0.05）。中药组不良反应明显轻于化疗组。结论:中药在晚期胰腺癌治疗中具有稳定瘤灶、延长患者生存期、药物不良反应少等优点

显示了良好的临床价值

值得进一步研究。

Abstract

Objective:To evaluate and compare the therapeutic effects of Chinese medicine and intra-arterial chemotherapy for stage Ⅳ pancreatic cancer patients.Methods:From May 2002 to July 2004

60 advanced pancreatic cancer in-patients were divided into two groups

Chinese medicine group （n=32） and chemotherapy group（n=28）.Clinical conditions were comparable between the two groups（P>0.05）.The objective effective rate

overall survival period

progression-free survival period and adverse effects of the medicine were analyzed and compared.Results:PR was 0

SD 53.1% and PD 46.9% in the Chinese medicine group

and PR7.1%

SD 53.6%

and PD 39.3% in the chemotherapy group

with no significant difference between the two groups（P>0.05）.In the Chinese medicine group

the one-year survival rate was 34.37% and the median survival period was 6.07 months

that was better than 11.25% and 4.17months in the chemotherapy group（P<0.05）.Toxicity in the Chinese medicine group was less than the chemotherapy group.Conclusion:Chinese medicine may benefit to advanced pancreatic cancer patient by stabilizing tumors and prolonging life expectancy

with less side effects than that of chemotherapy.

关键词

Keywords

references

查看原文

Views

440

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Therapeutic Effect of Chinese Drug Combined with Interventional Therapy on 33 Cases of Cardiac Carcinoma

Clinical Observation on Jianpi Liqi Recipe for Treatment of 25 Cases of Distal Metastasis of Liver Cancer

Construction and Application of a Real-World Cohort of Community-Acquired Pneumonia Based on a Multimodal Large-Scale Traditional Chinese Medicine Big Data Platform

Effect of Xiaoqinglong Decoction （小青龙汤） on Th2 Immune Responses and Nasal Mucosal TSLP/OX40L Pathway in Allergic Rhinitis Model Rats

A Preliminary Discussion on the Method of Regulating Qi and Calming the Mind

Related Author

苑静波

苏春芝

刘兆勋

啜振华

林钧华

郭伟剑

Related Institution

河北省中医院

河北省优抚医院

石家庄铁路中心医院石家庄市中山东路389号

上海复旦大学肿瘤医院中医科

上海第二医科大学新华医院肿瘤科上海市东安路270号

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰